AOCNP EXAM ADVANCED STUDY
GUIDE 2026/2027 QUESTIONS &
VERIFIED ANSWERS (A+ GUARANTEE)
1. A patient with metastatic non-small cell lung cancer (NSCLC) tests positive for the EGFR
T790M mutation after progressing on first-generation TKIs. Which treatment is indicated?
A. Erlotinib
B. Osimertinib
C. Gefitinib
D. Crizotinib
Answer: B
Conceptual Explanation: Osimertinib is a third-generation EGFR TKI specifically designed
to target the T790M resistance mutation, which is the most common mechanism of
resistance to first-generation EGFR inhibitors.
2. In a patient experiencing Tumor Lysis Syndrome (TLS), which of the following metabolic
abnormalities is typically observed?
A. Hypokalemia, hyperuricemia, hypophosphatemia, and hypocalcemia
B. Hypokalemia, hypouricemia, hypophosphatemia, and hypercalcemia
C. Hyperkalemia, hypouricemia, hyperphosphatemia, and hypercalcemia
,D. Hyperkalemia, hyperuricemia, hyperphosphatemia, and hypocalcemia
Answer: D
Conceptual Explanation: TLS involves the rapid release of intracellular contents, leading
to high potassium, uric acid, and phosphate, which subsequently causes calcium to
precipitate, leading to low serum calcium.
3. A patient on Nivolumab presents with Grade 3 diarrhea and abdominal pain. What is the
priority management step?
A. Hold Nivolumab and initiate high-dose corticosteroids (1-2 mg/kg/day)
B. Administer Loperamide and continue therapy
C. Switch to an alternative checkpoint inhibitor
D. Provide aggressive IV hydration and observe for 48 hours
Answer: A
Conceptual Explanation: Grade 3 immune-related colitis requires holding the
immunotherapy agent and starting systemic corticosteroids to suppress the immune-
mediated inflammatory response.
4. Which molecular marker is most predictive of response to Pembrolizumab across various
solid tumor types?
A. Microsatellite Instability-High (MSI-H)
B. KRAS mutation
, C. HER2 amplification
D. EGFR exon 19 deletion
Answer: A
Conceptual Explanation: MSI-H or dMMR status is a tissue-agnostic biomarker that
indicates a high likelihood of response to PD-1 inhibitors like Pembrolizumab.
5. A patient receiving Doxorubicin is at risk for cumulative dose-related cardiotoxicity. What
is the recommended lifetime cumulative dose limit to minimize this risk?
A. 300 mg/m2
B. 900 mg/m2
C. 700 mg/m2
D. 450-550 mg/m2
Answer: D
Conceptual Explanation: The risk of congestive heart failure increases significantly once
the cumulative dose of Doxorubicin exceeds 450-550 mg/m2.
6. What is the primary mechanism of action of Bevacizumab?
A. Inhibition of EGFR signaling
B. Binding to and neutralizing VEGF-A
C. Inhibition of the mTOR pathway
GUIDE 2026/2027 QUESTIONS &
VERIFIED ANSWERS (A+ GUARANTEE)
1. A patient with metastatic non-small cell lung cancer (NSCLC) tests positive for the EGFR
T790M mutation after progressing on first-generation TKIs. Which treatment is indicated?
A. Erlotinib
B. Osimertinib
C. Gefitinib
D. Crizotinib
Answer: B
Conceptual Explanation: Osimertinib is a third-generation EGFR TKI specifically designed
to target the T790M resistance mutation, which is the most common mechanism of
resistance to first-generation EGFR inhibitors.
2. In a patient experiencing Tumor Lysis Syndrome (TLS), which of the following metabolic
abnormalities is typically observed?
A. Hypokalemia, hyperuricemia, hypophosphatemia, and hypocalcemia
B. Hypokalemia, hypouricemia, hypophosphatemia, and hypercalcemia
C. Hyperkalemia, hypouricemia, hyperphosphatemia, and hypercalcemia
,D. Hyperkalemia, hyperuricemia, hyperphosphatemia, and hypocalcemia
Answer: D
Conceptual Explanation: TLS involves the rapid release of intracellular contents, leading
to high potassium, uric acid, and phosphate, which subsequently causes calcium to
precipitate, leading to low serum calcium.
3. A patient on Nivolumab presents with Grade 3 diarrhea and abdominal pain. What is the
priority management step?
A. Hold Nivolumab and initiate high-dose corticosteroids (1-2 mg/kg/day)
B. Administer Loperamide and continue therapy
C. Switch to an alternative checkpoint inhibitor
D. Provide aggressive IV hydration and observe for 48 hours
Answer: A
Conceptual Explanation: Grade 3 immune-related colitis requires holding the
immunotherapy agent and starting systemic corticosteroids to suppress the immune-
mediated inflammatory response.
4. Which molecular marker is most predictive of response to Pembrolizumab across various
solid tumor types?
A. Microsatellite Instability-High (MSI-H)
B. KRAS mutation
, C. HER2 amplification
D. EGFR exon 19 deletion
Answer: A
Conceptual Explanation: MSI-H or dMMR status is a tissue-agnostic biomarker that
indicates a high likelihood of response to PD-1 inhibitors like Pembrolizumab.
5. A patient receiving Doxorubicin is at risk for cumulative dose-related cardiotoxicity. What
is the recommended lifetime cumulative dose limit to minimize this risk?
A. 300 mg/m2
B. 900 mg/m2
C. 700 mg/m2
D. 450-550 mg/m2
Answer: D
Conceptual Explanation: The risk of congestive heart failure increases significantly once
the cumulative dose of Doxorubicin exceeds 450-550 mg/m2.
6. What is the primary mechanism of action of Bevacizumab?
A. Inhibition of EGFR signaling
B. Binding to and neutralizing VEGF-A
C. Inhibition of the mTOR pathway
